Characterizing medical care by disease phase in metastatic colorectal cancer
- PMID: 21886516
- PMCID: PMC3092457
- DOI: 10.1200/JOP.2011.000304
Characterizing medical care by disease phase in metastatic colorectal cancer
Abstract
Purpose: To characterize patterns of medical care by disease phase in patients with newly diagnosed metastatic colorectal cancer (mCRC).
Methods: Patients with mCRC newly diagnosed between 2004 and 2008 were selected from a large US national commercially insured claims database and were observed from initial mCRC diagnosis to death, disenrollment, or end of study period (July 31, 2009), whichever occurred first. The observation period was divided into three distinct phases of disease: diagnostic, treatment, and death. Within each phase, patterns of medical care were examined by the mutually exclusive service categories of inpatient, emergency room (ER), outpatient office and facility, outpatient pharmacy, chemotherapy, and biologic therapy, as measured by estimation of aggregate and category costs per patient per month.
Results: A total of 6,675 patients with newly diagnosed mCRC were analyzed. Mean age was 64.1 years; 55.5% were males. Mean costs per patient per month for diagnostic, treatment, and death phases were $16,895, $8,891, and $27,554, respectively. Inpatient care was the primary driver of medical care for both the diagnostic (41.7% of costs) and death (71.4% of costs) phases. The largest category of medical care for the treatment phase was outpatient care (45.0% of costs). Chemotherapy and biologic therapy accounted for 15.6% and 17.6% of costs in the treatment phase, respectively.
Conclusion: Substantial differences in patterns of medical care were found between mCRC disease phases. Inpatient care was the key driver of medical care in the diagnostic and death phases compared with outpatient care in the treatment phase.
Figures
Similar articles
-
Characterizing medical care by disease phase in metastatic colorectal cancer.Am J Manag Care. 2011 May;17 Suppl 5 Developing:SP20-5. Am J Manag Care. 2011. PMID: 21711074
-
Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer.Clin Colorectal Cancer. 2006 May;6(1):52-8. doi: 10.3816/CCC.2006.n.021. Clin Colorectal Cancer. 2006. PMID: 16796792
-
Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics.Curr Med Res Opin. 2011 Jan;27(1):123-30. doi: 10.1185/03007995.2010.536912. Epub 2010 Dec 6. Curr Med Res Opin. 2011. PMID: 21128878
-
Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population.J Med Econ. 2013 Dec;16(12):1379-86. doi: 10.3111/13696998.2013.848208. Epub 2013 Oct 18. J Med Econ. 2013. PMID: 24074258
-
Impact of metastatic colorectal cancer stage and number of treatment courses on patient health care costs and utilization.Postgrad Med. 2013 Mar;125(2):73-82. doi: 10.3810/pgm.2013.03.2642. Postgrad Med. 2013. PMID: 23816773
Cited by
-
Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer.Oncologist. 2019 Sep;24(9):1209-1218. doi: 10.1634/theoncologist.2018-0018. Epub 2019 Feb 22. Oncologist. 2019. PMID: 30796156 Free PMC article.
-
A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer.Front Oncol. 2022 Nov 24;12:1044328. doi: 10.3389/fonc.2022.1044328. eCollection 2022. Front Oncol. 2022. PMID: 36505849 Free PMC article.
-
Cost-effectiveness of adding Endocuff® to standard colonoscopies for interval colorectal cancer screening.Clinicoecon Outcomes Res. 2019 Jul 31;11:487-504. doi: 10.2147/CEOR.S201328. eCollection 2019. Clinicoecon Outcomes Res. 2019. PMID: 31447569 Free PMC article.
-
Risk of unplanned visits for colorectal cancer outpatients receiving chemotherapy: a case-crossover study.Support Care Cancer. 2014 Sep;22(9):2527-33. doi: 10.1007/s00520-014-2234-z. Epub 2014 Apr 13. Support Care Cancer. 2014. PMID: 24728616
References
-
- National Cancer Institute. Cancer Treatment (PDQ) http://www.cancer.gov/cancertopics/pdq/treatment/colon/healthprofessiona....
-
- Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–1544. - PubMed
-
- Kindler HL, Shulman KL. Metastatic colorectal cancer. Curr Treat Options Oncol. 2001;2:459–471. - PubMed
-
- Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan study group. N Engl J Med. 2003;343:905–914. - PubMed
LinkOut - more resources
Full Text Sources